Skip to main content

Medifast, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results

Revenue increased 17% in the Fourth Quarter and 42% for the Full Year

Introduces Full Year 2020 Outlook

BALTIMORE, Feb. 26, 2020 PRNewswire/ -- Medifast (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, which offers Lifelong Transformation, One Healthy Habit at a Time®, today reported results for the fourth quarter and full year ended December 31, 2019.

(PRNewsfoto/Medifast, Inc.)

Fourth Quarter 2019 Highlights Compared to Prior-Year Period

  • Revenue up 17.0% to $170.6 million
  • 32.0% growth in active earning OPTAVIA Coaches to 31,800
  • Net income increased 27.0% to $19.9 million
  • Earnings per diluted share ("EPS") of $1.66, an increase of 27.7%
  • Declared a quarterly cash dividend of $13.4 million, or $1.13 per share paid on February 6, 2020, an increase of over 50% compared to the prior-year period.

Full Year 2019 Highlights Compared to the Prior-Year Period

  • Revenue of $713.7 million, an increase of 42.4% year-over-year
  • Net income of $77.9 million, an increase of 39.7% year-over-year
  • EPS of $6.43, an increase of 39.2% year-over-year
  • Cash, cash equivalents, and investment securities of $92.7 million and the Company remains free of interest-bearing debt as of December 31, 2019

"We are pleased with our strong growth in revenue and active earning coaches during 2019 and are confident with our ability to drive continued gains in 2020 and beyond. We made excellent progress during the fourth quarter implementing our technology and supply chain upgrades, are seeing strong improvements in client satisfaction and are now better positioned to support our ongoing growth opportunities.  With the recent operational challenges that temporarily muted the growth of active earning Coaches and clients largely behind us, we expect to see our growth rate improve as the year progresses," said Dan Chard, Chief Executive Officer of Medifast. "2019 was a transformative year where we laid the foundations for global expansion, built the systems and infrastructure to support significant future growth and we believe further demonstrated that our growth model is sustainable long-term.  Our commitment to lifelong transformation one healthy habit at a time is unwavering across our organization.  We are confident in our ability to produce long-term growth for our Stockholders and remain committed to making ongoing improvements to the Coach and Client experience in 2020 and beyond. 

Fourth Quarter 2019 Results

Fourth quarter revenue increased 17.0% to $170.6 million from revenue of $145.8 million for the fourth quarter of 2018. OPTAVIA-branded products represented 79% of consumable units sold for the fourth quarter compared to 72% for the same period a year ago.

The total number of active earning OPTAVIA Coaches increased to 31,800, compared to 24,100 for the fourth quarter of 2018. The average revenue per active earning OPTAVIA Coach decreased 9.2% to $5,229 compared to $5,756 for the fourth quarter last year.

Gross profit increased 17.4% to $128.1 million from $109.1 million for the fourth quarter of 2018. The Company's gross profit as a percentage of revenue increased 30 basis points year-over-year to 75.1% from 74.8% primarily as a result of a mid-year price increase and improvements in costs related to inventory obsolescence, partially offset by customer concessions.   

Selling, general and administrative expenses ("SG&A") increased $20.1 million to $109.4 million compared to $89.3 million for the fourth quarter of 2018, primarily due to higher OPTAVIA commission expense, increased consulting costs related to technology initiatives, increased salaries and benefits. SG&A as a percentage of revenue increased 290 basis points year-over-year to 64.1% of revenue.

Operating income decreased $1.1 million to $18.7 million from $19.8 million in the prior-year period as increased gross profit was offset by increased SG&A expenses. Operating income as a percentage of revenue was 11.0% for the quarter, a decrease of 260 basis points from the year-ago period.

The effective tax rate for the quarter was a 4.7% benefit for the fourth quarter of 2019 compared to a 22.4% expense in the year-ago period.  The fourth quarter tax benefit reflected the impact of discrete federal tax benefits from share-based compensation, partially offset by increases in the effective state tax rate of 2.0%.

Fourth quarter net income was $19.9 million, or $1.66 per diluted share, based on approximately 11.9 million shares outstanding. The discrete federal tax benefit from share-based compensation had a $5.7 million impact on net income in the fourth quarter, or $0.47 per diluted share.  Fourth quarter 2018 net income was $15.7 million, or $1.30 per diluted share, based on approximately 12.0 million shares outstanding.   

Full Year Fiscal 2019 Results

For the fiscal year ended December 31, 2019, revenue increased 42.4% to $713.7 million compared to revenue of $501.0 million in 2018.  

Net income for 2019 was $77.9 million, or $6.43 per diluted share based on approximately 12.1 million shares outstanding, compared to $55.8 million, or $4.62 per diluted share for the comparable period last year based on approximately 12.1 million shares outstanding.

Balance Sheet

The Company's balance sheet remains strong with stockholders' equity of $104.8 million and working capital of $74.8 million as of December 31, 2019.  Cash, cash equivalents, and investment securities decreased $8.3 million to $92.7 million as of December 31, 2019 compared to $101.0 million at December 31, 2018. The Company remains free of interest-bearing debt.  Inventory increased $9.9 million to $48.8 million at December 31, 2019 compared to $38.9 million at December 31, 2018 as the Company increased inventory levels to support the launch of 32 new international products, initial production of the new Habits of Health system and a continued effort to meet current and future demand.

The Company declared a quarterly cash dividend of $13.4 million, or $1.13 per share that was paid on February 6, 2020. The Company did not repurchase any shares during the fourth quarter of 2019 and repurchased approximately 296,000 shares during fiscal year 2019.  There are approximately 2,369,000 shares of common stock remaining under the Company's share repurchase program. Medifast expects to maintain a program of paying dividends on a quarterly basis.

Outlook

The Company expects first quarter revenue to be in the range of $166.0 million to $171.0 million and EPS to be in the range of $1.35 to $1.42.  For the full year 2020, the Company expects revenue of $715.0 million to $745.0 million and EPS of $6.25 to $6.55. The full-year 2019 earnings guidance assumes a 22.5% to 23.5% effective tax rate.

Conference Call Information

The conference call is scheduled for today, Wednesday, February 26, 2020 at 4:30 p.m. ET. The call will be broadcast live over the Internet hosted at the Investor Relations section of Medifast's website at www.MedifastInc.com, and will be archived online through March 11, 2020. In addition, listeners may dial (855) 560-2579.

A telephonic playback will be available from 6:30 p.m. ET, February 26, 2020, through March 4, 2020. Participants can dial (877) 344-7529 to hear the playback and enter passcode 10139285.

About Medifast®:

Medifast (NYSE: MED) is the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, which offers Lifelong Transformation, One Healthy Habit at a Time®. Based on nearly 40 years of experience, Medifast has redefined direct selling by combining the best aspects of the model. Its community of thousands of independent OPTAVIA Coaches teach Clients to develop holistic healthy habits through products and clinically proven plans, the Habits of Health® Transformational System and comprehensive support from a community of like-minded people. In 2019, Medifast expanded the OPTAVIA movement globally, beginning with the Asia-Pacific region.  Medifast is traded on the New York Stock Exchange and was named to Fortune's 100 Fastest-Growing Companies list in 2019 and Forbes' 100 Most Trustworthy Companies in America List in 2016 and 2017. For more information, visit www.MedifastInc.com or www.OPTAVIA.com.

MED-F

Forward Looking Statements

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend," "anticipate," "expects" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent OPTAVIA Coaches and clients, Medifast's inability to prevent the use of stolen identities and credit cards outside of the Company's systems to transact business on the Company's e-commerce sites, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

MEDIFAST, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

Quarters and Years Ended December 31, 2019 and 2018

(in thousands, except per share amounts & dividend data)




Three months ended December 31,


Year ended December 31,



2019


2018


2019


2018














Revenue


$

170,632


$

145,844


$

713,672


$

501,003

Cost of sales



42,564



36,753



176,814



121,104

Gross profit



128,068



109,091



536,858



379,899














Selling, general, and administrative



109,361



89,288



445,819



310,836














Income from operations



18,707



19,803



91,039



69,063














Other income













Interest income, net



234



366



1,295



1,306

Other income



40



1



29



179




274



367



1,324



1,485














Income from operations before income taxes



18,981



20,170



92,363



70,548














Provision for income taxes



(900)



4,517



14,447



14,759














Net income


$

19,881


$

15,653


$

77,916


$

55,789














Earnings per share - basic


$

1.71


$

1.32


$

6.62


$

4.67














Earnings per share - diluted


$

1.66


$

1.30


$

6.43


$

4.62














Weighted average shares outstanding -













Basic



11,617



11,894



11,771



11,947

Diluted



11,947



12,014



12,117



12,079














Cash dividends declared per share


$

1.13


$

0.75


$

3.38


$

2.19

 

MEDIFAST, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

As of December 31, 2019 and 2018

(in thousands, except par value)






2019



2018











ASSETS


Current Assets









Cash and cash equivalents



$

76,974


$

81,364


Accounts receivable - net of doubtful accounts of $235 and $394 at









December 31, 2019 and 2018, respectively




1,437



1,011


Inventory




48,771



38,888


Investment securities




15,704



19,670


Income taxes, prepaid




5,169



-


Prepaid expenses and other current assets




6,096



4,586


Total current assets




154,151



145,519











Property, plant and equipment - net of accumulated depreciation




26,039



19,747


Right-of-use assets




12,803



-


Other assets




353



1,183


Deferred tax assets




1,307



2,980




















TOTAL ASSETS



$

194,653


$

169,429











LIABILITIES AND STOCKHOLDERS' EQUITY


Current Liabilities









Accounts payable and accrued expenses



$

76,220


$

60,323


Current lease obligations




3,168



-


Total current liabilities




79,388



60,323











Lease obligations, less current lease obligations




10,433



-


Total liabilities




89,821



60,323











Stockholders' Equity









Common stock, par value $.001 per share: 20,000 shares authorized;









12,272 and 12,117 issued and 11,764 and 11,868 outstanding









at December 31, 2019 and December 31, 2018, respectively




12



12


Additional paid-in capital




-



8,802


Accumulated other comprehensive income (loss)




25



(173)


Retained earnings




168,788



131,344


Less: Treasury stock at cost, 489 and 193 shares at December 31,









2019 and December 31, 2018, respectively




(63,993)



(30,879)


Total stockholders' equity




104,832



109,106











TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY



$

194,653


$

169,429


 

SOURCE Medifast, Inc.

For further information: ICR, Inc., Scott Van Winkle, scott.vanwinkle@icrinc.com, (617) 956-6736